Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 3043-3050

  Hegde, Sharath S ^a   Reyes, Noe ^a   Wiens, Tania ^a   Vanasse, Nicole ^a   Skinner, Robert ^a   McCullough, Julia ^a   Kaniga, Koné ^a   Pace, John ^a   Thomas, Roger ^a   Shaw, Jeng Pyng ^a   Obedencio, Glen ^a   Judice, J Kevin ^b  

^a THERAVANCE INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DRUG VEHICLE; LINEZOLID; METICILLIN; NAFCILLIN; PENICILLIN DERIVATIVE; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ENTEROCOCCUS FAECALIS; FEMALE; GRAM POSITIVE BACTERIUM; IMMUNE STATUS; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; ENDPOINT DETERMINATION; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; METHICILLIN RESISTANCE; MICE; MUSCLE, SKELETAL; NAFCILLIN; NEUTROPENIA; OXAZOLIDINONES; PROTEIN BINDING; STAPHYLOCOCCAL INFECTIONS; SUBCUTANEOUS TISSUE; VANCOMYCIN;

EID: 3342877329     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.3043-3050.2004     Document Type: Article

References (20)

1. Andes, D., and W. A. Craig. 2001. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268.
2. CDC NNIS System. 2001. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-June 2001, issued August 2001. Am. J. Infect. Control 29:404-421.
3. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States, 2002. Morbid. Mortal. Wkly. Rep. 51:565-567.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic paramaters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
5. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
6. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
7. Drusano, G. L. 1990. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand. J. Infect. Dis. Suppl. 74:235-248.
8. Drusano, G. L. 1988. Role of pharmacokinetics in the outcome of infections. Antimicrob. Agents Chemother. 32:289-297.
9. Gradelski, E., L. Valera, L., B. Kolek, D. Bonner, and J. Fung-Tomc. 2001. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. Int. J. Antimicrob. Agents 18:43-48.
10. Leggett, J. E., and W. A. Craig. 1989. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob. Agents Chemother. 33:35-40.
11. Liu, P., M. Muller, and H. Derendorf. 2002. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int. J. Antimicrob. Agents 19:285-290.
12. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2002. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int. J. Antimicrob. Agents 19:355-358.
13. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721.
14. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 5th ed. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Norrby, R. 2001. Linezolid - a review of the first oxazolidinone. Expert Opin. Pharmacother. 2:293-302.
16. Pace, J. L., K. Krause, D. Johnston, D. Debabov, T. Wu, L. Farrington, C. Lane, D. L. Higgins, B. Christensen, K. J. Judice, and K. Kaniga. 2003. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob. Agents Chemother. 47:3602-3604.
17. Renneberg, J., and M. Walder. 1988. A mouse model for simultaneous pharmacokinetic and efficacy studies of antibiotics at sites of infection. J. Antimicrob. Chemother. 22:51-60.
18. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, W. R. Jarvis, et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
19. Tally, F. P., and M. F. DeBruin. 2000. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46:523-526.
20. Whitney, C. G., M. M. Farley, J. Hadler, L. H. Harrison, C. Lexau, A. Reingold, L. Lefkowitz, P. R. Cieslak, M. Cetron, E. R. Zell, J. H. Jorgensen, and A Schuchat. 2000. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343:1917-1924.